252 559

Cited 7 times in

Increased Sclerostin Level after Further Ablation of Remnant Estrogen by Aromatase Inhibitors

DC Field Value Language
dc.contributor.author박세희-
dc.contributor.author배재현-
dc.contributor.author이수진-
dc.contributor.author이유미-
dc.contributor.author임승길-
dc.contributor.author김규리-
dc.contributor.author김원진-
dc.contributor.author김조은-
dc.contributor.author박병우-
dc.date.accessioned2016-02-04T11:15:10Z-
dc.date.available2016-02-04T11:15:10Z-
dc.date.issued2015-
dc.identifier.issn2093-596X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/140008-
dc.description.abstractBACKGROUND: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. METHODS: We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly assigned to take either 5 mg alendronate with 0.5 μg calcitriol (n=46), or placebo (n=44) for 6 months. RESULTS: Postmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopausal women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P<0.05). Baseline sclerostin levels positively correlated with either lumbar spine or total hip bone mineral density only in postmenopausal women (r=0.218 and r=0.233; P<0.05, respectively). Serum sclerostin levels increased by 39.9%±10.2% 6 months after AI use in postmenopausal women; however, no difference was observed between the alendronate and placebo groups (39.9%±10.2% vs. 55.9%±9.13%, P>0.05). CONCLUSION: Serum sclerostin levels increased with absolute deficiency of residual estrogens in postmenopausal women with endocrine-responsive breast cancer who underwent AI therapy with concurrent bone loss.-
dc.description.statementOfResponsibilityopen-
dc.format.extent58~64-
dc.relation.isPartOfEndocrinology and Metabolism (대한내분비학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleIncreased Sclerostin Level after Further Ablation of Remnant Estrogen by Aromatase Inhibitors-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorWonjin Kim-
dc.contributor.googleauthorYoonjung Chung-
dc.contributor.googleauthorSe Hwa Kim-
dc.contributor.googleauthorSehee Park-
dc.contributor.googleauthorJae Hyun Bae-
dc.contributor.googleauthorGyuri Kim-
dc.contributor.googleauthorSu Jin Lee-
dc.contributor.googleauthorJo Eun Kim-
dc.contributor.googleauthorByeong Woo Park-
dc.contributor.googleauthorSung Kil Lim-
dc.contributor.googleauthorYumie Rhee-
dc.identifier.doi10.3803/EnM.2015.30.1.58-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01525-
dc.contributor.localIdA01803-
dc.contributor.localIdA03012-
dc.contributor.localIdA03375-
dc.contributor.localIdA00322-
dc.contributor.localIdA00772-
dc.contributor.localIdA00911-
dc.contributor.localIdA01475-
dc.contributor.localIdA02894-
dc.relation.journalcodeJ00773-
dc.identifier.pmid25827459-
dc.subject.keywordAromatase inhibitors-
dc.subject.keywordBreast neoplasms-
dc.subject.keywordOsteoporosis-
dc.subject.keywordSclerostin-
dc.contributor.alternativeNamePark, Se Hee-
dc.contributor.alternativeNameBae, Jae Hyun-
dc.contributor.alternativeNameLee, Su Jin-
dc.contributor.alternativeNameRhee, Yumie-
dc.contributor.alternativeNameLim, Sung Kil-
dc.contributor.alternativeNameKim, Gyuri-
dc.contributor.alternativeNameKim, Won Jin-
dc.contributor.alternativeNameKim, Jo Eun-
dc.contributor.alternativeNamePark, Byeong Woo-
dc.contributor.affiliatedAuthorPark, Se Hee-
dc.contributor.affiliatedAuthorBae, Jae Hyun-
dc.contributor.affiliatedAuthorRhee, Yumie-
dc.contributor.affiliatedAuthorLim, Sung Kil-
dc.contributor.affiliatedAuthorKim, Gyuri-
dc.contributor.affiliatedAuthorKim, Won Jin-
dc.contributor.affiliatedAuthorKim, Jo Eun-
dc.contributor.affiliatedAuthorPark, Byeong Woo-
dc.contributor.affiliatedAuthorLee, Su Jin-
dc.rights.accessRightsfree-
dc.citation.volume30-
dc.citation.number1-
dc.citation.startPage58-
dc.citation.endPage64-
dc.identifier.bibliographicCitationEndocrinology and Metabolism (대한내분비학회지), Vol.30(1) : 58-64, 2015-
dc.identifier.rimsid49023-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.